Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
CoA, Coenzyme A
The Phase 3 SYNERGY trial (NCT06859268) will evaluate whether retatrutide can resolve steatohepatitis (liver inflammation) and fibrosis, endpoints that would be required for regulatory approval specifically for liver disease treatment
They're the difference between a solution that retains 95% bioactivity and one that retains 50%
It is a convenient choice for multi-dose use and helps reduce the need to open a new vial for every injection
Presented for research literature review only Kostaropoulos I et al
Exercise plus liraglutide
US$ 25.34
US$ 21.22
US$ 26.25
US$ 25.03
